Abstract. Postoperative immunosuppression is associated with the recurrence and metastasis of esophageal squamous cell carcinoma (ESCC). Propofol is a commonly used intravenous anesthetic and has been reported to be associated with immunosuppression; however, little is known about its effect on innate immune cells during the postoperative period in patients with ESCC. The aim of the present study was to investigate the effects of propofol on the phenotype and cytotoxicity of natural killer (NK) cells derived from the peripheral blood of patients with ESCC. The percentage, phenotype and function of NK cells were compared between patients with ESCC and healthy volunteers using flow cytometry. NK cells were negatively sorted using magnetic beads and cocultured with propofol to assess changes in phenotype and function. The results revealed that the percentage of NK cells was significantly increased in the peripheral blood of patients with ESCC, while their activity and cytotoxicity were impaired. NK cells were successfully separated from peripheral blood in vitro and it was demonstrated that propofol enhanced their activity by influencing the expression of activating or inhibitory receptors. Furthermore, propofol was able to increase the cytotoxicity of NK cells from the peripheral blood of patients with ESCC. These results suggest that propofol is able to improve the function of NK cells in patients with ESCC and may therefore be an appropriate anesthetic for ESCC surgery.
Introduction
Esophageal carcinoma is one of the most common digestive tract-derived malignancies worldwide (1, 2) . Esophageal carcinoma is comprised of squamous carcinoma and adenocarcinoma (3). A high incidence of esophageal squamous carcinoma (ESCC) has been reported in China (4); in 2015, 429,200 cases of cancer were reported in China, with 281,400 mortalities (5) . Of these cases, 259,000 were ESCC, making it the fifth most prevalent malignant tumor (6) . Tumor recurrence and metastasis are leading causes of mortality in patients with ESCC (7) . It has previously been reported that immunosuppression is associated with tumor recurrence and metastasis (8, 9) , however the underlying mechanism remains to be elucidated.
It is well established that immunosuppression is associated with the recurrence and metastasis of multiple tumors (10) . The immune response of infiltrating lymphocytes in tumor tissues is impaired by certain components in the tumor microenvironment, which leads to tumor recurrence and metastasis (11, 12) . Furthermore, it has been reported that restoration of the immune system may improve the survival of patients with ESCC (13) . It has been demonstrated that various anesthetic agents exert different but important effects on immune cells in patients with tumors (14) . It may therefore be beneficial to select an anesthetic that improves immunosuppression in patients with tumors.
Innate immunity is the body's first line of defense against infection, tumors and virus invasion (15) . Compromised innate immunity has been reported in a number of tumor types and is associated with the survival of patients with tumors, suggesting a crucial role of innate immunity in the inhibition of tumors (16) . Natural killer (NK) cells are an important component of the innate immune system, they are typically cluster of differentiation (CD)3 -CD56 + cells, which and are primarily distributed in the peripheral blood, with 10-15% in lymphocytes (17, 18) . NK cells are responsible for immune surveillance without antigen presentation and major histocompatibility complex (MHC) restriction (19) . Once activated, NK cells are able to recognize target cells rapidly and release cytotoxic effector molecules to trigger the immune response (20 
Results
The phenotype and function of NK cells from the peripheral blood of patients with ESCC. NK cells have been reported to be important for suppressing the recurrence and metastasis of tumor cells. Furthermore, it has been reported that immunosuppression occurs in the tumor microenvironment as well as the peripheral blood (23) . The results of flow cytometry revealed that the percentage of NK cells gated by CD3-CD56+ in the peripheral blood of patients with ESCC (21.6±0.89%) was significantly increased compared with the control (11.8±0.54%; Fig. 1 ). Furthermore, the percentage of NKT cells gated by CD3+CD56+, another type of innate immune cell (24) , was significantly increased in the peripheral blood of patients with ESCC compared with the control group (3.99±0.43 vs. 1.15±0.10); Fig. 1 ), indicating that the innate immune response activity was increased. NK cell activation is known to be controlled by activating and inhibitory receptors (25) . In the present study, the expression of activating and inhibitory receptors was assessed to evaluate the activity and function of NK cells. The results revealed that the expression of activating receptors of CD16, NKG2D, CD226 and p30 were significantly increased in compared with the control group (Fig. 2) . However, no significant difference in p44, p46, CD158b, G2A, granzyme B, perforin, IFNγ and TNFα expression was observed (Fig. 3) . The cytotoxicity of NK cells to K562 was assessed by detecting the expression of CD107a in NK cells. It was demonstrated that the number of CD107a+ NK cells was significantly increased in patients with ESCC compared with the healthy controls, suggesting that the cytotoxicity of NK cells is reduced in patients with ESCC (Fig. 2) . Ki67+ cells were also counted to evaluate the proliferation potential of NK cells. No significant difference in proliferation was observed between groups (Fig. 3) . These data suggest that the function of NK cells in the peripheral blood of patients with ESCC is impaired compared with those from healthy subjects.
Purification and identification of NK cells.
To further investigate the potential influence of propofol on NK cells in ESCC, NK cells were negatively isolated using magnetic beads sorting (26) . CD3-CD56+ cells associated with the lymphocyte gate by forward scatter (FSC) and side scatter (SSC) on a dot-plot were defined as NK cells. The results demonstrated that the number of sorted NK cells from the peripheral blood of patients with ESCC or healthy volunteers was 3.5±0.25x10 5 or 2.7±0.11x10 5 , respectively, while the purity of NK cells was >90% and the percentage of CD3+ T cells was <1%, suggesting that the sorting of NK cells was successful and suitable for subsequent experiments (Fig. 4) .
Surface markers of NK cells as detected by flow cytometry.
To investigate the impact of propofol on NK cells, the phenotype of isolated NK cells cocultured with propofol was assessed. A concentration of 50 µmol/l propofol was selected as this has been reported to be an appropriate concentration for studying its function (27) . The expression of activating and inhibitory receptors on the surface of NK cells was determined using flow cytometry. The results revealed that the percentage of several activating receptors was significantly increased in NK cells cocultured with propofol compared with the control group, including CD16, NKp30, NKp44 and NKG2D (Fig. 5) . Conversely, the expression of inhibitory receptors CD158b and NKG2A was significantly decreased in NK cells treated with propofol compared with the control group (Fig. 5) . No significant differences in NKp44, NKp46 and CD226 expression was observed (data not shown). These data suggest that propofol may enhance the activity of NK cells in ESCC by regulating the equilibrium between activating and inhibitory receptors. (Fig. 6) , suggesting that NK cell cytotoxicity was increased. These data suggest that propofol may promote the cytotoxicity of NK cells from patients with ESCC.
Propofol enhances the expression of granzyme B and IFN-γin
NK cells. It is well established that activated NK cells destroy tumor cells mainly via cytotoxicity effector molecules, including granzyme B, perforin, IFN-γ and TNF-α (28). The results of flow cytometry revealed that the expression of granzyme B and IFN-γ was significantly increased following incubation with propofol
Propofol promotes the proliferation potential of isolated NK cells. The influence of propofol on the proliferation potential of isolated NK cells was assessed by detecting expression of Ki67 through flow cytometry.
The results demonstrated that the number of Ki67+ NK cells was significantly higher following propofol stimulation compared with control cells (Fig. 7) . These data suggest that propofol may promote the proliferative potential of NK cells in patients with ESCC.
Propofol enhances the function of NK cells in vitro.
Based on previous findings, the cytotoxicity of NK cells cocultured with propofol to tumor cells was assessed in vitro using apoptosis analysis. K562 was selected as the target cell line as it does not express MHCI molecules (29) . The apoptosis rate of K562 cells cocultured with NK cells stimulated by propofol was significantly higher compared with the control group (Fig. 8) .
To further investigate the cytotoxicity of NK cells to ESCC cells, the apoptosis rate of Eca109 cells incubated with NK cells was assessed. Consistent with K562, NK cells cultured with propofol exerted a greater cytotoxic effect on Eca109 cells compared with the control (Fig. 8) . These data suggest that propofol may enhance the cytotoxicity of NK cells from the peripheral blood of patients with ESCC.
Discussion
Elucidating the effect of anesthesia on immune inhibition during the postoperative period is essential for preventing tumor metastasis and improving the prognosis of patients with ESCC (30) . Although anesthetic agents have been demonstrated to affect tumor recurrence and metastasis (31) , the impact of anesthetics on anti-tumor immune cells is not well understood. In the present study, NK cells were successfully isolated from the peripheral blood of patients with ESCC and it was confirmed that propofol is able to increase the activity of NK cells by regulating the expression of receptors and cytotoxicity effect molecules. Furthermore, propofol enhances the cytotoxicity of NK cells to ESCC cells in vitro, indicating that it serves as a promotion effector for the postoperative immune system in ESCC.
NK cells are a group of innate lymphoid cells, which serve a crucial role in the inhibition of multiple tumors (32) . A novel tumor therapy technique, adoptive immunotherapy, based on NK cells has been investigated in human trials (33) . The activation or inhibition of NK cells has been reported to depend on the recognition of altered tumor cells by the activation or inhibition of receptors on the NK cell surface. Therefore, screening factors that influence the expression of NK cell surface receptors is a critical area of immunotherapy for tumors (34) . Anesthetics have been reported to be associated with innate immune system regulation, providing a novel perspective that anesthesia was implicated with tumor recurrence and metastasis by regulation of immune response (35) . The cytotoxicity of NK cells from patients with breast cancer receiving propofol-remifentanil anesthesia with postoperative ketorolac analgesia was clearly lower compared with those receiving sevoflurane-remifentanil anesthesia with postoperative fentanyl analgesia (36); Inada et al (37) reported that propofol promotes the expression of IFNγ in NK cells by suppressing prostaglandin E2 (37) . This suggests that propofol is associated with the regulation of NK cytotoxicity; however, its impact on the expression of activation and inhibitory receptors remains unclear. Consistent with previous studies (38) , the percentage of NK cells from patients with ESCC was increased compared with the control, which may be a response to tumorigenesis. The phenotype and cytotoxicity of NK cells was investigated and the results demonstrated that NK cells from patients with ESCC had a higher expression of activating receptors (p30, NKG2D, CD226 and CD16) compared with the control, suggesting that NK cells from the peripheral blood of patients with ESCC were activated. Conversely, it has previously been reported that NK cells patients with tumors had impaired function (39, 40) . These contradictory results may be because some crucial signaling pathway downstream of activating receptors also serves a role in the regulation of NK cells,.
To further evaluate the effect of propofol on NK cells, isolated NK cells from patients with ESCC were incubated and granzyme B. Ki67 was also upregulated in NK cells stimulated with propofol, indicating that propofol improves the proliferation potential of NK cells. Although data within the present study indicated that propofol probably promoted the activation of NK cells from patients with ESCC, the cytotoxicity of NK cells still needs to be confirmed. Blocking the activating interaction between activating receptors and matched ligands led to impaired NK cell function in the presence of high expression of activating receptors. The cytotoxic effects of NK cells on K562 and Eca109 were investigated and it was revealed that propofol-stimulated NK cells increased apoptosis in K562 and Eca109 cells. Furthermore, a significant increase in CD107a + NK cells, which are characteristic of degranulation, was observed following propofol stimulation. These data suggest that propofol is able to enhance the cytotoxic effects of NK cells from the peripheral blood of patients with ESCC in vitro. In the present study, the number of patients recruited was insufficient to analyze the association between NK cell markers and clinicopathological characteristics, including lymph node metastasis and TNM stage. Furthermore, the function of propofol on NK cells should be verified using an in vivo mouse model in the future.
In conclusion, the results of the present study demonstrated that propofol is able to enhance the function of NK cells from the peripheral blood of patients with ESCC. Based on these results, propofol may have the potential to improve postoperative immunosuppression in patients with ESCC. 
